Comparison of Rheological Properties of Healthy versus Dupuytren Fibroblasts When Treated with a Cell Contraction Inhibitor by Atomic Force Microscope

Int J Mol Sci. 2023 Jan 20;24(3):2043. doi: 10.3390/ijms24032043.

Abstract

Mechanical properties of healthy and Dupuytren fibroblasts were investigated by atomic force microscopy (AFM). In addition to standard force curves, rheological properties were assessed using an oscillatory testing methodology, in which the frequency was swept from 1 Hz to 1 kHz, and data were analyzed using the structural damping model. Dupuytren fibroblasts showed larger apparent Young's modulus values than healthy ones, which is in agreement with previous results. Moreover, cell mechanics were compared before and after ML-7 treatment, which is a myosin light chain kinase inhibitor (MLCK) that reduces myosin activity and hence cell contraction. We employed two different concentrations of ML-7 inhibitor and could observe distinct cell reactions. At 1 µM, healthy and scar fibroblasts did not show measurable changes in stiffness, but Dupuytren fibroblasts displayed a softening and recovery after some time. When increasing ML-7 concentration (3 µM), the majority of cells reacted, Dupuytren fibroblasts were the most susceptible, not being able to recover from the drug and dying. These results suggested that ML-7 is a potent inhibitor for MLCK and that myosin II is essential for cytoskeleton stabilization and cell survival.

Keywords: Dupuytren’s disease; ML-7; atomic force microscopy; fibroblast; inhibition; rheology.

MeSH terms

  • Cytoskeleton* / drug effects
  • Cytoskeleton* / metabolism
  • Cytoskeleton* / physiology
  • Cytoskeleton* / ultrastructure
  • Dupuytren Contracture* / drug therapy
  • Dupuytren Contracture* / metabolism
  • Dupuytren Contracture* / pathology
  • Fibroblasts* / drug effects
  • Fibroblasts* / metabolism
  • Humans
  • Mechanical Phenomena
  • Microscopy, Atomic Force*
  • Muscle Contraction* / drug effects
  • Muscle Contraction* / physiology
  • Myosin Light Chains* / metabolism
  • Myosin-Light-Chain Kinase / pharmacology
  • Myosin-Light-Chain Kinase / therapeutic use

Substances

  • ML 7
  • Myosin Light Chains
  • Myosin-Light-Chain Kinase

Grants and funding

This project was funded by the H2020 European Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement “Phys2BioMed” contract no. 812772.